The new generation of Non-Invasive Prenatal Testing (NIPT) it analyzes the cell free fetal DNA in the mother’s blood to detect chromosomal abnormalities in the fetus.
Is defined as the onset, after week 20 of the pregnancy, of: Hypertension - Proteinuria (presence of proteins in urine) The test benefits from incorporating the placental growth factor PlGF along with other ultrasound and biochemical factors to provide early detection of PE with high sensitivity.
CardioScore Clinical and genetic assessment of the real cardiovascular risk It
A200 Analysis of food intolerance, It is a test which allows the measure of levels on Specific Immunoglobuline G against
Oncology Liquid biopsy tumor DNA sequencing, it utilizes NGS to monitor known tumor mutations in 50 established cancer- associated genes